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Background: We evaluated the prognostic importance of DNA ploidy in stage I and II endometrioid adenocarcinoma
(EAC) of the endometrium with a focus on DNA index.
Patients and methods: High-resolution DNA ploidy analysis was carried out in tumor material from 937 consecutive
patients with International Federation of Gynecology and Obstetrics (FIGO) stage I and II EAC of the endometrium.
Results: Patients with diploid (N = 728), aneuploid tumor with DNA index £1.20 (N = 118), aneuploid tumors with
DNA index >1.20 (N = 39) and tetraploid tumor (N = 52) had 5-year recurrence rates 8%, 14%, 20% and 12%,
respectively. Patients with aneuploid tumor with DNA index >1.20 had a poorer 5-year progression-free survival (67%)
and overall survival (72%) compared with the patients with aneuploid tumor with DNA index £1.20 (81% and 89%,
respectively). Aneuploid tumors with DNA index £1.20 relapsed mainly in the vagina and pelvis, whereas aneuploid
tumors with DNA index >1.20 relapsed predominantly outside pelvis.
Conclusions: The recurrence risk for the patients with aneuploid tumor is higher than the patients with diploid tumor
in EAC of the endometrium. Based on DNA index with cut-off 1.20, aneuploid tumors can be separated into two
subgroups with different recurrence pattern and survival.
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introduction
The important prognostic factors for patients with endometrial
carcinoma include the pathological stage of the disease, the
extent of myometrial invasion, lymphovascular invasion (LVI)
and histological subtype [1,2]. In addition to these factors,
DNA ploidy of the tumor has been reported as a prognostic
factor [3–6], even in routine diagnostic setting [7]. The patients
with diploid tumor have better survival compared with those
with aneuploid tumor. In addition, DNA ploidy has been used
to identify a subgroup of patients in need of adjuvant therapy
[8–10].
Modern high-resolution image cytometry enables better
detection of near-diploid peaks. This is usually difﬁcult in ﬂow
cytometric DNA ploidy analysis from parafﬁn-embedded
material [11], the method used in the majority of studies [5, 7,
8, 10, 12–14]. Whether minor deviation in tumor cell DNA
content has a clinical relevance is still unknown.
Endometrial carcinoma is a histologically heterogeneous entity
ranging from less-aggressive tumor such as endometrioid
adenocarcinoma (EAC) grade 1 to highly aggressive malignancy
such as serous adenocarcinoma [15]. In most of the DNA ploidy
studies, all the histological subtypes are included in the analyses
making the interpretation of DNA ploidy ﬁndings in a deﬁnite
subtype difﬁcult [3, 16, 17]. Furthermore, DNA ploidy statuses
and the DNA index (DI) of aneuploid tumor are associated with
the histological subtypes [18]. In order to evaluate the prognostic
importance of DNA ploidy and DI, we have studied a large series
of tumors from patients with EAC in stage I and II with a follow-
up of at least 4 years.
patients and methods
We have carried out a study of the consecutive patients with endometrial
carcinoma who were referred to the Norwegian Radium Hospital (NRH),
Oslo University Hospital from September 1998 to February 2006. The NRH
is one of the four teaching cancer centers for gynecologic oncology and
serves mainly as the regional cancer hospital for the Southeast region of
Norway covering 56% of the total population of Norway. The samples for
DNA ploidy analysis were prospectively collected. Based on hematoxylin
and eosin (H&E) stained sections, the most representative block containing
tumor from curettage or hysterectomy specimens were selected.
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blood) were marked and processed for DNA ploidy analysis. Only the cases
with stage I and II disease with histological subtype EAC were included in
the study. Patients with additional cancer, cases without representative
tissue in the control H&E section, cases with diploid tumors with a high
coefﬁcient of variation (CV) of the peak (>5) were excluded. Furthermore,
ﬁve patients with an aneuploid tumor diagnosed by 5c exceeding rate (5c
ER) >1% (percentage of nuclei with a DNA content 2.5 times more than
diploid nuclei) and one patient with a polyploid tumor were not included
in the analysis due to the low numbers. Finally, 937 patients remained for
the analyses. The information on stage [International Federation of
Gynecology and Obstetrics (FIGO) 1988], recurrence and LVI was obtained
from the clinical and pathology reports. The data on death were acquired
from the Center Bureau of Statistics, which registers all deaths based on the
death certiﬁcates transmitted by the patients’ physicians. DNA ploidy
analysis was carried out in hysterectomy specimen in 686 and in curettage
specimen in 251 cases. The treatment protocol for the period was
abdominal hysterectomy with bilateral salpingo-oophorectomy. Pelvic and
para-aortic lymphadenectomy were carried out if suspicious of metastasis.
Additional radiotherapy and/or chemotherapy were given to 62 and 20
patients with high-risk, respectively. DNA ploidy diagnosis was not taken
into consideration for the adjuvant therapy of the patients. The patients
with recurrence were treated with radiotherapy, chemotherapy, hormonal
therapy or surgery depending on the localization of the recurrence and the
hormone receptors’ expression of the tumor. Ethical approval of the study
was obtained from the Regional Committee for Medical and Health
Research Ethics, Southeastern Norway.
histology of the tumors
Without knowledge of the outcome, all histology slides from the area, from
which DNA ploidy was carried out, were reviewed by two pathologists (MP
and BR). In discordant cases, a third gynecologic pathologist (VA) was
consulted in order to reach consensus. The tumors were classiﬁed and
graded according to World Health Organization recommendation [15]. We
used reviewed diagnosis for the analysis as it has been shown to be
prognostically better than initial routine diagnosis [12].
DNA image cytometry
The monolayers, prepared from 50-lm sections from parafﬁn-embedded
blocks, were stained by Feulgen method as described in detail previously
[18]. The DNA content in nuclei was measured using Ploidy Work Station
(Room 4, Kent, UK), which consists of Zeiss Axioplan microscope (Zeiss,
Jena, Germany) equipped with a 546-nm green ﬁlter and a high-resolution
digital camera. Integrated optical density (IOD) was calculated by
multiplying the measured optical density and the area of each nucleus. The
nuclear images were edited and grouped into different galleries for tumor
nuclei, reference nuclei and discarded nuclei. DNA ploidy histograms were
created from IOD of the nuclei using PWS Classiﬁer (Room 4, Kent, UK).
The mean IOD of a non-diploid peak was divided by the mean IOD of the
diploid peak to compute DI. Using the reference nuclei as an internal
diploid control, DNA ploidy histograms were classiﬁed into diploid,
aneuploid, tetraploid and polyploid according to the criteria described
earlier [18]. In order to ﬁnd out the prognostic importance of near-diploid
peaks, aneuploid tumors were further grouped into aneuploid tumors with
DI 1.06–1.20 and aneuploid tumors with DI >1.20. DI, 5c ER and 9c ER
were registered additionally.
reproducibility of DNA ploidy histogram evaluation
To evaluate the reproducibility of DNA ploidy histogram evaluation, 102
cases (10%) were randomly selected, and the DNA ploidy results were
evaluated by another pathologist (BR).
statistical analysis
Progression-free survival (PFS) was calculated from the date of surgery to
recurrence or 31 August 2010 and both recurrence and death due to any
cause were considered as events. Overall survival (OS) was calculated from
the date of surgery to death or 15 December 2010 and death due to any
cause was considered as an event. The Kaplan–Meier method and the log-
rank test were used for univariate survival analysis. Cox proportional
hazard regression analysis with backward stepwise elimination was used for
multivariate survival analysis. Variables with P < 0.20 in univariate survival
analysis were included in the model. Chi-square test was used to test the
association between DI and histological grades. Fisher’s exact test was
carried out to test the association between subgroups of aneuploid tumors
and the site of recurrences. The reproducibility of DNA ploidy diagnosis
and DI were evaluated by using Cohen’s kappa coefﬁcient and intraclass
correlation coefﬁcient. CV of the IOD of diploid peaks was calculated for
the quality assurance of histograms. All statistical tests were two-sided and
P-values £0.05 were regarded as statistically signiﬁcant. Statistical analysis
was done with SPSS (Statistical Package for the Social Sciences) version 16
(SPSS Inc., Chicago, IL).
results
patient characteristics
The median age of the patients at the time of diagnosis was 64
years (mean 64, range 35–95 years). There were 181 patients in
stage IA, 467 in stage IB, 164 in IC, 73 in IIA and 52 in IIB. By
histological evaluation, 613 tumors were grade 1, 237 were grade
2 and 87 were grade 3 (Table 1). LVI was present in 16% cases
(147 out of 905). In 32 cases, LVI data were not available. Both
pelvic and para-aortic lymphadenectomy were carried out in 72
(8%) and only pelvic lymphadenectomy was carried out in 159
(17%) patients. The recurrences were detected in the vagina (41
cases), in the pelvis (18 cases) and outside pelvis in 36 cases.
image cytometric DNA ploidy
The mean and median CV of the diploid peak in the DNA
ploidy analyses were 2.9 and 2.8, respectively. The mean
number of nuclei analyzed was 601 (median 300, range
99–1620). Most of the tumors were diploid (728 cases, 78%).
Among the 157 aneuploid tumors, 118 (13%) had a DI between
1.06 and 1.20 and 39 (4%) had a DI >1.2 (Table 2, Figure 1),
whereas 52 (6%) were tetraploid. In 867 cases, 5c ER was <1%
and ‡1% in 70 cases. Tumors with DI £1.20 were mainly found
in histological grade 1 and 2, whereas those with DI >1.2 were
more frequent in grade 3 (P < 0.01, Table 3).
survival analyses
At the date of last follow-up, 95 patients had recurred and 190
were dead due to any cause. The 5-year recurrence rate, PFS
and OS 6 standard error for all patients were 10 6 1%, 84 6
1% and 89 61%, respectively. The 5-year recurrence rates for
diploid, aneuploid with DI £1.20, aneuploid with DI >1.20 and
tetraploid tumors were 8%, 14%, 20% and 12%, respectively
(Table 2). Diploid and aneuploid tumors with DI £1.20
relapsed mainly in the vagina (Table 2). In contrast, aneuploid
tumor with DI >1.20 relapsed outside pelvis (six cases, Table 2).
The association of recurrence site and DI of aneuploid tumors
was not statistically signiﬁcant in spite of a big difference in
proportions (Fisher’s exact test, P = 0.09). This was probably
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DI >1.20 had signiﬁcantly poorer PFS and OS than the patients
with diploid tumor (Figure 2). Age (P <0.01), FIGO stage (P <
0.01), grade (P < 0.01), LVI (P < 0.01) and DNA ploidy (P <
0.03) were signiﬁcantly associated with both PFS and OS (log-
rank test). In multivariate analysis using Cox proportional
hazard regression, age (P < 0.01), histological grade (P = 0.01),
LVI (P < 0.01) and FIGO stage (P < 0.01) were prognostic
factors for PFS, whereas age (P < 0.01), LVI (P < 0.01) and
grade (P = 0.03) were prognostic for OS (Table 4). We
additionally carried out multivariate analysis using recurrence
as an endpoint. Only age (P < 0.01), FIGO stage (P < 0.01),
grade (P = 0.04) and LVI (P = 0.03) were retained in the
model (Table 4). Dichotomized 5c ER with cut-off 1% showed
borderline prognostic signiﬁcance for PFS in the univariate
analysis (P = 0.07). Furthermore, we analyzed OS in patients
with recurrence in order to evaluate the response to salvage
therapy in different DNA ploidy subgroups. The overall P-value
for all subgroups was 0.04 (log-rank test). When the subgroups
were tested pairwise, only the patients with diploid and
tetraploid tumors differed signiﬁcantly (P < 0.01). No
signiﬁcant difference in OS in the patients with recurrence was
observed between diploid, aneuploid with DI 1.06–1.20 and
aneuploid with DI >1.20 subgroups.
We further evaluated whether the specimen used for DNA
ploidy analysis has any impact in prognostication. DNA ploidy
results from hysterectomy specimen (P < 0.01) were superior
compared with results from curettage specimen (P = 0.76)
to prognosticate biological behavior in patients with this
tumor.
Table 1. Recurrence rate, PFS and OS based on various prognostic factors in patients with stage I and II endometrioid adenocarcinoma of the
endometrium
Variables Categories Number of
patients (%)
Number of
recurrences
(%)
Number of
deaths (%)
Recurrence site 5-year
recurrence
rate 6 SE
(%)
5-year PFS 5 year OS
Vagina
(%)
Pelvis
(%)
Outside
pelvis (%)
PFS 6 SE
(%)
P-value
a OS 6 SE
(%)
P-value
a
Age (years) <65 485 (52) 28 (6) 34 (7) 10 (36) 3 (11) 15 (54) 5 6 19 3 6 1 <0.01 96 6 1 <0.01
‡65 452 (48) 67 (15) 156 (35) 31 (46) 15 (22) 21 (31) 15 6 27 4 6 28 2 6 2
FIGO stage IA 181 (19) 1 (1) 24 (13) 0 0 1 (100) 1 6 19 4 6 2 <0.01 94 6 2 <0.01
IB 467 (50) 46 (10) 79 (17) 24 (52) 7 (15) 15 (33) 9 6 18 6 6 29 1 6 1
IC 164 (18) 22 (13) 53 (32) 12 (55) 3 (14) 7 (32) 14 6 37 6 6 38 1 6 3
IIA 73 (8) 15 (21) 22 (30) 3 (20) 5 (33) 7 (47) 20 6 56 8 6 58 1 6 5
IIB 52 (6) 11 (21) 12 (23) 2 (18) 3 (27) 6 (55) 20 6 67 7 6 68 5 6 5
Grade 1 613 (65) 47 (8) 99 (16) 23 (49) 12 (26) 12 (26) 7 6 18 8 6 1 <0.01 92 6 1 <0.01
2 237 (25) 30 (13) 64 (27) 14 (47) 3 (10) 13 (43) 12 6 28 1 6 38 6 6 2
3 87 (9) 18 (21) 27 (31) 4 (22) 3 (17) 11 (61) 22 6 56 7 6 57 7 6 5
LVI
b Absent 758 (84) 62 (8) 131 (17) 32 (52) 11 (18) 19 (31) 8 6 18 6 6 1 <0.01 91 6 1 <0.01
Present 147 (16) 31 (21) 53 (36) 8 (26) 6 (19) 17 (55) 21 6 37 1 6 47 8 6 3
Total 937 (100) 95 (10) 190 (20) 41 (43) 18 (19) 36 (38) 10 6 18 4 6 18 9 6 1
FIGO, International Federation of Gynecology and Obstetrics; LVI, lymphovascular invasion; OS, overall survival; PFS, progression-free survival; SE,
standard error.
aOverall P-value by log-rank test.
bData not available in 32 cases.
Table 2. Recurrence rate, PFS and OS of patients with stage I and II endometrioid adenocarcinoma of the endometrium based on DNA ploidy
Variables Categories Number of
patients (%)
Number of
recurrences
(%)
Number of
deaths (%)
Recurrence site 5-year
recurrence
rate 6 SE
(%)
5-year PFS 5-year OS
Vagina
(%)
Pelvis
(%)
Outside
pelvis (%)
PFS 6 SE
%
P-value
a OS 6 SE
%
P-value
a
DNA
ploidy
Diploid 728 (78) 63 (9) 136 (19) 29 (46) 13 (21) 21 (33) 8 6 18 5 6 1 0.03 90 61 0.02
Aneuploid
(DI £1.20)
118 (13) 18 (15) 27 (23) 9 (50) 3 (17) 6 (33) 14 6 38 1 6 48 9 6 3
Aneuploid
(DI >1.20)
39 (4) 8 (21) 14 (36) 1 (13) 1 (13) 6 (75) 20 6 76 7 6 87 2 6 7
Tetraploid 52 (6) 6 (12) 13 (25) 2 (33) 1 (17) 3 (50) 12 6 58 3 6 58 5 65
Total 937 (100) 95 (10) 190 (20) 41 (43) 18 (19) 36 (38) 10 6 18 4 6 18 9 6 1
DI, DNA index; OS, overall survival; PSF, progression-free survival; SE, standard error.
aOverall P-value by log-rank test.
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ploidy histogram and histology of a patient with aneuploid tumor with DNA index (DI) 1.08. The patient had recurrence after 8 months (C, D). An
aneuploid tumor with DI 1.44, the patient had recurrence in liver, upper abdominal cavity and inguinal lymph nodes after 15 months (E, F).
Table 3. DNA ploidy subgroups in relation to other parameters in endometrial endometrioid adenocarcinoma
Parameters DNA ploidy
Diploid (%) Aneuploid, DI £1.20 (%) Aneuploid, DI >1.20 (%) Tetraploid (%) Total
Age <65 384 (79) 58 (12) 16 (3) 27 (6) 485
‡65 344 (76) 60 (13) 23 (5) 25 (5) 452
Grade 1 517 (84) 75 (12) 9 (2) 12 (2) 613
2 169 (71) 37 (16) 15 (6) 16 (7) 237
3 42 (48) 6 (7) 15 (17) 24 (28) 87
Stage IA 140 (77) 22 (12) 7 (4) 12 (7) 181
IB 359 (77) 64 (14) 17 (4) 27 (6) 467
IC 134 (82) 15 (9) 10 (6) 5 (3) 164
IIA 55 (75) 11 (15) 3 (4) 4 (6) 73
IIB 40 (77) 6 (12) 2 (4) 4 (8) 52
LVI
a Absent 598 (79) 94 (12) 25 (3) 41 (5) 758
Present 101 (69) 22 (15) 14 (10) 10 (7) 147
Specimen Curettage 193 (77) 20 (8) 12 (5) 26 (10) 251
Hysterectomy 535 (78) 98 (14) 27 (4) 26 (4) 686
DI, DNA index; LVI, lymphovascular invasion.
aData not available in 32 cases.
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In the reproducibility study of 102 samples, DNA ploidy diagnoses
were identical in 97 cases with a very good agreement (Cohen
j = 0.89). Intraclass correlation coefﬁcient for DI was 0.94.
discussion
The DNA ploidy has repeatedly been reported as an important
prognostic factor for patients with endometrial carcinoma by
many investigators [3, 5, 6, 13]. Generally, the DNA ploidy
results are grouped into two, namely, diploid and non-diploid
(aneuploid and tetraploid together) [8, 19–21] or euploid
(diploid and tetraploid together) and aneuploid [12]. We,
earlier, observed that the histological subtypes of endometrial
carcinoma associate with DNA ploidy status and DI. Most of
the aneuploid EAC had DI £1.20, whereas aneuploid serous
adenocarcinoma had DI >1.60. Furthermore, bimodal
distribution of DI was seen in endometrial carcinoma [18].
Therefore, we identiﬁed four distinct DNA ploidy groups,
namely, diploid, tetraploid, aneuploid tumors with a peak near
to diploid peak (DI 1.06 to 1.20) and aneuploid tumors with
a peak toward tetraploid peak (DI >1.20). The prognostic
importance of these subgroups of DNA ploidy has not
been studied. Moreover, endometrial carcinoma is
a heterogeneous cancer with different aggressiveness ranging
from less-aggressive tumor as EAC grade 1 to highly aggressive
tumors such as serous and clear-cell adenocarcinomas. EAC is
a different entity than serous and clear-cell adenocarcinomas
regarding morphology [15], molecular expression [4],
oncogenesis [22] and prognosis [23–25]. We, therefore,
analyzed a relatively large series of EACs of the endometrium
and found that these four DNA ploidy subgroups have different
recurrence and survival patterns. To the best of our knowledge,
this is the ﬁrst report analyzing the prognostic importance of
subgroups of aneuploid tumor in EAC.
The aneuploid tumors with DI £1.20 were mainly found in
grade 1 and grade 2 tumors and were three times more
prevalent than aneuploid tumors with DI >1.20 (Table 2,
Figure 1). We are not aware of any DNA ploidy studies
speciﬁcally investigating the importance of near-diploid
aneuploid tumors. Earlier, Atkins [26], using cytogenetic
analysis, reported hyperdiploid populations in EAC with an
additional chromosome and considered those prognostically
favorable. We found that a minor DNA content deviation
(DI £1.20) indicated a signiﬁcantly higher risk for recurrence
compared with the patients with diploid tumors, whereas the
PFS and OS were not signiﬁcantly different. Additionally, these
tumors relapse mainly in the vagina and pelvis similar to
diploid tumors. This might indicate that patients with
aneuploid tumor with DI £1.20 can be followed up or be
considered for vaginal brachytherapy. In a study by Mangili
et al. [9], the patients with aneuploid tumor with DI £1.20 were
grouped along with the patients with diploid tumor in order to
take a decision regarding adjuvant therapy.
In contrast to the aneuploid tumors with DI £1.20, the
aneuploid tumors with DI >1.20 were clinically aggressive and
relapsed mainly outside pelvis similar to serous and clear-cell
adenocarcinomas [27, 28], indicating that these patients can be
potential candidates for chemotherapy. The incidence of
tumors with DI >1.20 was found to be higher in grade 3 tumors
than in grade 1 and 2 tumors (Table 3). The patients had
signiﬁcantly poorer PFS and OS than the patients with diploid
tumor. Similar to our result, Mariani et al. [19] reported that
DI >1.50 was a predictor for distant failure. However, they
Figure 2. The Kaplan–Meier curves of cumulative incidence of recurrence
(A), progression-free survival (B) and overall survival (C) of different
DNA ploidy subgroups.
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into one group and aneuploid tumor with DI >1.50 and
tetraploid into another group.
In EAC, there is no data in the existing literature on the
prognostic importance of tetraploidy since these tumors either
were included in diploid [12] or in the aneuploid group [14].
In this series, we found a signiﬁcant number of tetraploid
tumors (52 cases, 5.4%) and the recurrence rate for these
patients was slightly higher compared with the patients with
diploid tumor. The PFS and OS of the patients with tetraploid
tumor were intermediate between the patients with diploid and
aneuploid tumors (Table 2, Figure 2), ﬁndings similar to
ovarian carcinomas [29]. Furthermore, the patients with
recurrent tetraploid tumor had worse OS compared with the
patients with other recurrent tumors in this series.
Initially, we believed that the DNA ploidy results from
hysterectomy and curettage specimens were interchangeable.
Subsequently, after terminating the study, we found that the DNA
ploidy results differed in the specimens in approximately
one-fourth of the cases [30]. We found that DNA ploidy results
from hysterectomy specimen provided better prognostic
information compared with curettage specimen. This ﬁnding is
also supported by the results in a relatively large series by Baak
et al. [12]; however, other investigators reported that curettage
specimen was useful for prognostication as well [31, 32]. The
possible explanation might be that the biology of the deep
inﬁltrating part of a tumor, which is best represented in
hysterectomy specimen, plays a more important role in recurrence
than the superﬁcial part of the tumor obtained in curettage
specimen [12]. Therefore, we believe that whenever possible,
hysterectomy specimen should be used for DNA ploidy analysis.
In multivariate analysis in endometrial carcinoma, DNA
ploidy has been reported as a prognostic marker by many
investigators [3, 4, 11, 14]. However, multivariate analyses were
carried out in a limited number of cases and events [33], using
dichotomized DNA ploidy with dissimilar criteria for
classiﬁcation [3, 9, 17], and incorporating usually aneuploid
type 2 carcinoma [3, 11]. Therefore, it is difﬁcult to draw
a conclusion on the prognostic superiority DNA ploidy over
the traditional prognostic markers in the existing literature. In
our series, only traditional prognostic markers retained
statistical signiﬁcance in multivariate analysis (Table 4).
Therefore, DNA ploidy results along with other established
parameters have to be taken in consideration for
prognostication of the patients with endometrial carcinoma.
Most of the reported works on DNA ploidy were carried out
by ﬂow cytometry [5, 7, 8, 12–14], although image cytometry
was found to be better in ﬁnding aneuploid subpopulations
than ﬂow cytometry [34]. Image cytometry enables discarding
cut nuclei and duplets from the analysis and nuclei can be
grouped in different galleries so that reference cells do not
interfere in DNA ploidy analysis resulting in a more accurate
result. Furthermore, the reproducibilities of the DNA ploidy
diagnoses and DI were found to be very good (j = 0.89). We
additionally studied the prognostic importance of other DNA
ploidy parameters, namely, S-phase and 5c ER. They did not
add any further information than DNA ploidy and DI (data not
shown).
In conclusion, DI of the aneuploid tumor has to be taken into
consideration in DNA ploidy results as the two subgroups had
different recurrence pattern and survivals. The patients with
aneuploid tumor with DI >1.20 had higher recurrence rate,
higher distant failure rate and poorer PFS and OS. The patients
with aneuploid tumors with DI £1.20 relapsed mainly locally and
had higher recurrence rate than the patients with diploid tumor.
These ﬁndings suggest that extent of gross genomic aberration
inﬂuences on cancer progression, implying further research.
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